Free Trial

Trading of BioNexus Gene Lab was halted at 09:31 AM EST due to "LULD pause".

BioNexus Gene Lab (BGLC) Competitors

BioNexus Gene Lab logo
$6.31 -0.51 (-7.49%)
Closing price 03:59 PM Eastern
Extended Trading
$6.33 +0.02 (+0.32%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BGLC vs. ENZ, BRTX, MGRX, SSY, OTRK, ACON, DHAC, ATIP, VSEE, and NIVF

Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Enzo Biochem (ENZ), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), Ontrak (OTRK), Aclarion (ACON), Digital Health Acquisition (DHAC), ATI Physical Therapy (ATIP), VSee Health (VSEE), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry.

BioNexus Gene Lab vs. Its Competitors

Enzo Biochem (NYSE:ENZ) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Enzo Biochem has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 5.08, indicating that its share price is 408% more volatile than the S&P 500.

BioNexus Gene Lab has a net margin of -22.85% compared to Enzo Biochem's net margin of -75.34%. Enzo Biochem's return on equity of -7.96% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Enzo Biochem-75.34% -7.96% -5.49%
BioNexus Gene Lab -22.85%-24.18%-20.14%

In the previous week, BioNexus Gene Lab had 6 more articles in the media than Enzo Biochem. MarketBeat recorded 7 mentions for BioNexus Gene Lab and 1 mentions for Enzo Biochem. Enzo Biochem's average media sentiment score of 0.00 equaled BioNexus Gene Lab'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enzo Biochem
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioNexus Gene Lab
0 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioNexus Gene Lab has lower revenue, but higher earnings than Enzo Biochem.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzo Biochem$29.09M0.59-$26.08MN/AN/A
BioNexus Gene Lab$9.51M1.19-$1.60MN/AN/A

36.9% of Enzo Biochem shares are held by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are held by institutional investors. 11.4% of Enzo Biochem shares are held by insiders. Comparatively, 0.7% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Enzo Biochem and BioNexus Gene Lab tied by winning 5 of the 10 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGLC vs. The Competition

MetricBioNexus Gene LabMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$12.25M$7.29B$5.54B$8.95B
Dividend YieldN/A2.78%5.38%4.08%
P/E RatioN/A27.9427.4020.04
Price / Sales1.1932.39419.46118.60
Price / CashN/A22.0836.6357.47
Price / Book1.366.698.085.67
Net Income-$1.60M$233.06M$3.16B$248.47M
7 Day Performance132.80%2.20%2.12%2.90%
1 Month Performance82.87%4.93%4.43%5.75%
1 Year Performance33.47%35.84%35.62%21.36%

BioNexus Gene Lab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGLC
BioNexus Gene Lab
0.3685 of 5 stars
$6.31
-7.5%
N/A+44.6%$12.25M$9.51M0.0030News Coverage
Gap Down
Trading Halted
ENZ
Enzo Biochem
N/A$0.33
-14.8%
N/A-69.6%$17.03M$29.09M0.00520Gap Down
High Trading Volume
BRTX
Biorestorative Therapies
2.7741 of 5 stars
$1.71
+4.0%
$18.00
+955.7%
-17.2%$12.79M$400K-1.167News Coverage
MGRX
Mangoceuticals
0.8748 of 5 stars
$2.03
+8.9%
N/A-97.8%$10.47M$620K-0.443News Coverage
Gap Down
SSY
SunLink Health Systems
N/A$0.92
-5.0%
N/A+23.1%$6.49M$31.09M6.591,376
OTRK
Ontrak
2.7435 of 5 stars
$1.06
-20.7%
$45.00
+4,165.4%
-84.2%$4.45M$10.85M-0.07250News Coverage
ACON
Aclarion
2.5567 of 5 stars
$6.97
-2.0%
$11,758.50
+168,722.7%
-99.7%$4.04M$50K0.007Positive News
DHAC
Digital Health Acquisition
N/A$1.12
+2.8%
N/A-86.8%$4.04MN/A0.002,021Gap Up
High Trading Volume
ATIP
ATI Physical Therapy
0.2086 of 5 stars
$0.88
-12.9%
N/A-79.6%$3.88M$741.86M-0.055,600Gap Down
VSEE
VSee Health
1.7983 of 5 stars
$1.07
-4.5%
$5.00
+367.3%
N/A$3.86M$6.38M0.00N/AGap Up
NIVF
NewGenIvf Group
N/A$1.09
-0.4%
N/A-99.5%$576K$5.43M0.00N/ANews Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:BGLC) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners